Damora Therapeutics (DMRA) Free Cash Flow (2019 - 2026)
Damora Therapeutics (DMRA) posted Free Cash Flow of -$20.6 million for Q1 2026, down 1533.4% on a QoQ basis from $1.4 million in Q4 2025, and down 695.29% year-over-year from $3.5 million in Q1 2025.
Damora Therapeutics (DMRA) Free Cash Flow (2019 - 2026) Analysis & Trends
Damora Therapeutics' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$20.6 million for Q1 2026.
- Quarterly Free Cash Flow fell 695.29% year-over-year to -$20.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.5 million (down 78.64% YoY) and the FY2025 annual result came in at -$6.5 million, up 62.94% from the prior year.
- Free Cash Flow was -$20.6 million for Q1 2026 at Damora Therapeutics, down from $1.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $1.4 million in Q4 2025 and bottomed at -$20.6 million in Q1 2026.
- A 5-year average of -$7.3 million and a median of -$6.8 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2025 — Free Cash Flow jumped 148.61% — and 2026, when it tumbled 695.29%.
- Damora Therapeutics' Free Cash Flow stood at -$11.5 million in 2022, then grew by 11.91% to -$10.2 million in 2023, then surged by 70.95% to -$3.0 million in 2024, then soared by 148.61% to $1.4 million in 2025, then tumbled by 1533.4% to -$20.6 million in 2026.
- Business Quant data shows DMRA's Free Cash Flow at -$20.6 million in Q1 2026, $1.4 million in Q4 2025, and -$2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | -20.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.60 Mn |
| Mar 31, 2026 | -20.60 Mn |
| Dec 31, 2025 | 1.44 Mn |
| Dec 31, 2025 | 1.44 Mn |
| Sep 30, 2025 | -2.92 Mn |
| Sep 30, 2025 | -2.92 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | -2.59 Mn |
| Mar 31, 2025 | -2.59 Mn |
| Dec 31, 2024 | -2.96 Mn |
| Dec 31, 2024 | -2.96 Mn |
| Sep 30, 2024 | -3.82 Mn |
| Sep 30, 2024 | -3.82 Mn |
| Jun 30, 2024 | -4.38 Mn |
| Jun 30, 2024 | -4.38 Mn |
| Mar 31, 2024 | -6.48 Mn |
| Mar 31, 2024 | -6.48 Mn |
| Dec 31, 2023 | -10.17 Mn |
| Dec 31, 2023 | -10.17 Mn |